PubMed Health⌕ Search

SEARCH · PubMed Health

Results for “DIETHYLSTILBESTROL”

Explore indexed PubMed citations for clinical trials, systematic reviews and public health research. Read source abstracts and follow each citation to its original PubMed record.

Quote a phrase for an exact phrase match. Source license links do not imply unrestricted reuse.

At least 1,009 records · Page 56Linked to original sources

Modifications in the low mobility group nuclear proteins by reactive metabolites of diethylstilbestrol.

In this study we have investigated the potential of nuclear activation system to convert diethylstilbestrol (DES) to reactive metabolites, which bind to low mobility nonhistone nuclear proteins. Reaction of DES with nuclei in the presence of cumene hydroperoxide or NADPH revealed binding of DES in low mobility group (LMG) nonhistone nuclear proteins analyzed by both organic solvent extraction and gel electrophoresis methods. Gel electrophoresis experiments revealed that five LMG proteins of MW 130, 108, 72, 51, and 45 KDa were irreversibly bound to 3H-DES. The kinetic constants, Km and Vmax, of this binding reaction in the presence of cumene hydroperoxide were 39 uM and 1225 pmol/mg protein/30 min, respectively. This binding was significantly inhibited by cytochromes P450 inhibitors. Low molecular weight thiols, i.e., glutathione and cysteine, or thiol modifiers such as n-ethylmaleimide, dithionitrobenzoic acid, and hydroxymercuric benzoate, drastically inhibited binding. The binding of DES metabolites to both transcriptionally active and inactive chromatins LMG proteins was observed. In summary, DES is metabolized to transcriptionally active chromatin LMG protein binding metabolites presumably by nuclear cytochromes P450. These data suggest that an analogous in vivo modification in the transcriptionally active chromatin LMG nonhistone proteins by DES metabolites may influence gene transcription.

Animals↗

Diethylstilbestrol alters the morphology and calcium levels of growth cones of PC12 cells in vitro.

Diethylstilbestrol (DES) is a synthetic estrogen with carcinogenic properties. DES is known to alter cytoskeletal components, including the organization of actin stress fibres in C6 rat glioma cells. In a test of the hypothesis that DES disrupts actin filaments of growth cones in neuron-like cells, DES-induced changes in filopodial lengths were quantified in rat pheochromocytoma (PC12) cells in vitro. DES significantly altered growth cone morphology, with collapse of growth cone filopodia and neurite retraction invariably occurring at a concentration of 10 microM. At 5 microM DES, transient reductions in total filopodial lengths occurred. At DES concentrations of 0.1 nM and 1 nM, reductions in total filopodial lengths occurred in a fraction of growth cones. Evidence exists which shows that growth cone activity and morphology are intimately linked to levels of intracellular, free calcium and that DES increases such levels. Measurements of free intracellular calcium levels by fluorescence microscopy, at times concurrent with the DES-induced reduction in total filopodial lengths, showed that calcium levels were indeed significantly increased by 10 microM DES. Labelling of filamentous actin (f-actin) with FITC-phalloidin showed that the f-actin distribution in growth cones exposed to DES could not be differentiated from the distribution found in spontaneously retracting growth cones. Together with evidence which showed that growth cone motility was not affected, the results are taken to indicate that DES, rather than acting directly on the cytoskeleton, exerts its effects indirectly, by a calcium-induced destabilization of actin filaments in the growth cone.

Actins↗

The fate of diethylstilbestrol in the pregnant mouse.

There is much current interest in the effect of diethylstilbestrol (DES) on the mammalian fetus; however, little is known concerning the physiologic disposition of DES during pregnancy. Radiolabeled (14C or 3H) DES (30 mug/kg) was given to 16-day pregnant mice and its metabolism, distribution and excretion were studied. After i.v. administration, DES was rapidly cleared from the plasma. The plasma decay rates could be described by the sum of four exponentials having T 1/2 values of 4 seconds, 1.1 minutes, 14 minutes and 13 hours. Moreover, conjugated products of DES accounted for more than one-half of the plasma radioactivity by 5 minutes after dosing. The parent compound was rapidly distributed to blood cells, but the liver was the major site of accumulation of DES and its metabolites. In fact, the total radioactivity in this organ accounted for 50% of the injected dose within 2.5 minutes after treatment. Significant concentrations of radioactivity persisted in liver throughout the 16-hour experiment, with DES conjugates accounting for 80% of the hepatic 14C activity at all time points examined. Approximately 56% of the dose was excreted in the feces within 24 hours, primarily as the parent compound. With DES as substrate, significant levels of UDP-glucuronyltransferase were determined in maternal and fetal liver but not in maternal uterus, placenta of fetal gut. Although the mouse placenta appeared to retard the passage of DES into the fetal compartment, a 3-fold accumulation (relative to fetal plasma) of the compound was found in the fetal reproductive tract.

Animals↗

The determination of diethylstilbestrol (DES) in the faeces and tissues of chickens treated with DES and in the faeces and tissue samples of calves, lambs and chickens collected from various areas of Turkey.

Diethylstilbestrol (DES) analyses were carried out on muscle, liver, kidney and faeces samples of 20 control and 20 experimental broilers to which 5 mg DES/day had been given orally for a period of 7 days. The treated samples were analysed using the Radioimmunoassay method. The removal time of DES from the tissues was determined. Five days following the final administration of DES, its faecal concentration was 151 ppb. However, 7 days after the final administration faecal DES concentrations increased again. On the first day after the final DES administration, DES concentrations in the liver, muscle and kidney were 0.78, 0.74 and 1.33 ppb, respectively. While these values measured on the final day were within the range of the control values. There was an increase of DES in plasma at the end of the experimental period. A total of 1811 muscle, liver, kidney and faeces samples of calves, lambs and chickens and feed samples collected from various areas in Turkey were analysed for the presence of DES. Positive samples for chicken feed was 36.9%. Also 1.9% of the chicken faeces samples were DES positive. All other samples were negative for DES.

Animals↗

Paraparesis due to metastatic prostatic cancer effectively treated with a high dose of diethylstilbestrol diphosphate: a case report.

A case of paraparesis due to thoracic vertebula metastasis of prostate cancer is reported. Treatment through a high dose of diethylstilbestrol diphosphate (DES-P) was very effective. Two and a half years later, the patient is ambulatory and relapse has not occurred. We recommend the use of a high dose of DES-P for spinal cord compression due to prostate cancer, instead of laminectomy or radiation.

Aged↗

Simple and rapid gas-liquid chromatographic determination of diethylstilbestrol in biological specimens.

Diethylstilbestrol (DES) is readily extracted into toluene from biological fluids or tissue homogenates. Sodium carbonate is added to the initial mixture to eliminate potentially interfering substances. The toluene is extracted with a very small volume of aqueous trimethylphenylammonium hydroxide. This solution generates dimethyl DES in the vaporizer of a gas-liquid chromatograph. An internal standard, dienestrol (DI), is added at the beginning of the procedure and is partitioned and methylated in the same manner as DES. The DES and DI derivatives are well separated in less than 6 min on an ov-17 column. The entire analysis requires less than 15 min for a fluid specimen and less than 25 min for a solid tissue specimen. Seven samples can be analyzed each hour on a single column with a flame ionization detector. The relative standard deviations at levels from 2.5 to 100 ppm in bile are less than 5%. The lower limit of sensitivity is 8 ppb in a 1 ml bile sample.

Animals↗

Formation of free radicals and active oxygen species from diethylstilbestrol and its derivatives.

Diethylstilbestrol (DES), an estrogen analogue, was converted into a free radical in alkaline dimethyl sulfoxide as well as in an H2O2/peroxidase system. The presence of the hydroxyl group of the DES molecule was essential to free radical formation. Indenestrol A (IA), a microsomal metabolite of DES, showed a paramagnetic property without enzymatic activation. The electron spin resonance spectrum of IA seemingly corresponded to that of the enzymatically formed DES radical. In an NADH/peroxidase system, DES induced concomitant production of active oxygen species, which were also produced by IA. Related compounds of IA were also examined to compare with DES and IA. The significance of the free radical is discussed in relation to the process of carcinogenesis by DES.

Dienestrol↗

Pituitary tumors in mice exposed prenatally to diethylstilbestrol.

Hyperprolactinemia and prolactinomas are among the abnormalities reported for women exposed prenatally to diethylstilbestrol (DES). To pursue this issue in an animal model replicating the other abnormalities of prenatal DES exposure, pituitary glands were studied in the offspring of CD-1 mice receiving an i.p. injection of 1 or 2 micrograms DES/g body weight during late pregnancy. Among 132 mice exposed prenatally to DES and then raised to terminal illness, there were 24 pituitary tumors compared to only 1 tumor among 64 controls. The tumors consisted predominantly of cells with an eccentric nucleus and cytoplasm characterized by an acidophilic core and basophilic rim. These cells were identified as lactotrophs on the basis of prolactin immunohistochemistry and by an expected variation in frequency relative to physiological states. Evaluation of ovaries from the same mice revealed a deficiency of corpora lutea and an elevated incidence of ovarian tumors. These findings are consistent with abnormal sex differentiation of the fetal hypothalamus being the cause of most adverse effects from prenatal DES exposure.

Animals↗

Breast cancer in mothers prescribed diethylstilbestrol in pregnancy. Further follow-up.

OBJECTIVE: Further assessment of the long-term risk of breast cancer associated with diethylstilbestrol (DES) during pregnancy. DESIGN: Follow-up continuation through June 1, 1989, of a historical cohort of DES-exposed and unexposed mothers ascertained by review of obstetric records. PARTICIPANTS: Totals of 3029 each of DES-exposed and unexposed mothers who had delivered live babies at four centers in the United States during 1940 through 1960. Questionnaires were returned for 92.6% of the DES-exposed and 88.8% of the unexposed women. MAIN OUTCOME MEASURES: Breast cancer incidence and mortality assessed from returned questionnaires and review of medical records and death certificates. MAIN RESULTS: The relative rate of breast cancer associated with DES exposure, after adjustment for demographic and reproductive variables, was 1.35 (95% confidence interval, 1.05 to 1.74). For 30 years or more following exposure, the relative rate was not appreciably higher (relative rate, 1.33; 95% confidence interval, 0.95 to 1.87) than that in earlier periods. Surveillance and increased detection seemed unlikely explanations for the increased risk, since DES-exposed women had excesses of both large and small breast cancers and the two cohorts reported similar breast cancer detection practices. A history of miscarriage before first term delivery was not associated with breast cancer occurrence. CONCLUSION: Exposure to DES during pregnancy is associated with a modest but statistically significant increased risk of breast cancer. Contrary to prior indications, the risk does not appear to increase greatly over time. The findings are sufficient to exclude the possibility of a doubling of risk for the period of 30 or more years following exposure.

Abortion, Spontaneous↗

Persistent changes in protein synthesis by vagina of ovariectomized mice exposed neonatally to diethylstilbestrol.

Neonatal treatment of female mice with a synthetic estrogen, diethylstilbestrol (DES), results in adenosis, ovary-independent epithelial proliferation and cornification, and downgrowths in the vagina. Protein synthesis was examined in the vagina of 45-day-old, ovariectomized C57BL/Tw mice which had been given 5 daily injections of 2 micrograms DES or the oil vehicle alone from the day of birth, and in those of age-matched, ovariectomized mice given 3 daily injections of 0.1 microgram DES from 42 days of age. [35S]Methionine-labeled proteins of the vagina were analyzed by two-dimensional polyacrylamide gel electrophoresis. Major changes were observed in 11 proteins of the vagina in both neonatally and postnatally DES-exposed groups. Six of the 11 proteins were increased in expression, but one of the remaining proteins was decreased. In the group of neonatally DES-exposed mice alone, expressions of 4 proteins (MW. 128, 90, 46 and 44 kDa) were markedly increased. These results indicate that neonatal exposure of mice to DES induced ovary-independent, persistent alteration in the protein synthesis of the vagina.

Animals↗

Microglandular hyperplasia in vaginal adenosis associated with oral contraceptives and prenatal diethylstilbestrol exposure.

Eight cases of microglandular hyperplasia arising in vaginal adenosis are presented. Five of the patients were known to have taken oral contraceptives and a sixth was pregnant at the time the lesion was discovered; a history of prenatal exposure to diethylstilbestrol (DES) was present in 5 cases. It is important to differentiate microglandular hyperplasia, which is benign, from clear cell adenocarcinoma, which also arises in a background of vaginal adenosis.

Adenocarcinoma↗

Comparison of magnetic resonance imaging and transvaginal ultrasonography with hysterosalpingography in the evaluation of women exposed to diethylstilbestrol.

OBJECTIVE: To compare the ability of magnetic resonance imaging (MRI) and transvaginal ultrasound (TV-US) with that of hysterosalpingography (HSG) in detecting uterine abnormalities caused by in utero diethylstilbestrol (DES) exposure. STUDY DESIGN: The study was a prospective MRI and TV-US blind comparison of DES-exposed and nonexposed subjects who had had previous HSG for infertility evaluation. RESULTS: MRI identified uterine constrictions in 60% of patients and T-shaped uteri in 25% of DES-exposed patients with HSG-confirmed abnormalities. TV-US did not identify uterine constrictions or T-shaped uteri in DES-exposed patients. CONCLUSION: HSG must still be considered the preferred method in evaluating DES-related uterine abnormalities. HSG-defined uterine abnormalities associated with in utero DES exposure were variably identified by MRI and not at all by TV-US.

Abnormalities, Drug-Induced↗

The effect of angiotensin II receptor antagonists on diethylstilbestrol-induced vascular changes in the rat anterior pituitary gland: a quantitative evaluation.

The effects if diethylstilbestrol (DES) and of angiotensin II (Ang II) receptor antagonists, such as losartan (selective AT1 receptor antagonist) or PD 123319 (selective AT2 receptor antagonist) on the anterior pituitary microvasculature were studied by means of computer-assisted image analysis. The vascularization was visualized using Selye's method modified by Poely et al. (1964). It was found that DES induced a sharp increase in vessel area, mean vessel diameter and perimeter, whereas mean vessel number was reduced. These DES-induced changes were inhibited by simultaneous administration of losartan. On the other hand, PD 123319 was less effective. These findings suggest an involvement of Ang II, acting mainly via AT1 receptors, in the mechanism of estrogen-induced vascular changes in the rat anterior pituitary gland.

Angiotensin II↗

Abolition of the diethylstilbestrol reduction of enzyme leakage from muscle by a 3,3' diallyl substitution.

Diethylstilbestrol (DES) lowers enzyme efflux from isolated mouse skeletal muscle. It also lowers the high serum enzyme activities in Duchenne's muscular dystrophy. We have begun a systematic study of DES congeners, to identify those portions of the DES molecule which are critical to these effects, and to tailor a molecule which might have fewer feminizing effects. The first compound tested was the 3,3' diallyl derivative of DES (DAS). It was selected because previous reports indicated that it was as anabolic as DES, but only 1/10 to 1/30 as estrogenic. Doses of 20, 100 and 250 microgram/mouse/day were administered in 0.05 ml sesame seed oil vehicle to C57BL/6 mice. Control animals received only the vehicle. In contrast to DES which has consistently reduced muscle enzyme efflux 30-50%, DAS was inert. The substitution of the two allyl groups in the 3 and 3' positions blocks access to the neighboring ethyl groups and partially covers the two phenolic hydroxyl groups of DES. This suggests that these molecular sites have pertinence to the reduction of enzyme efflux from mouse skeletal muscle by DES, and possibly the reduction of the high serum enzyme activities in Duchenne's muscular dystrophy.

Allyl Compounds↗

Neonatal diethylstilbestrol treatment alters the estrogen-regulated expression of both cell proliferation and apoptosis-related proto-oncogenes (c-jun, c-fos, c-myc, bax, bcl-2, and bcl-x) in the hamster uterus.

In the Syrian hamster, neonatal diethylstilbestrol (DES) treatment and then postpubertal estrogen stimulation induces hyperplasia plus apoptosis (preneoplastic responses) and ultimately neoplasia in the endometrial epithelial cell compartment. As part of a project to investigate the molecular and cellular mechanisms responsible for this phenomenon, expression of several proto-oncogenes (c-jun, c-fos, c-myc, bax, bcl-2 and bcl-x) was compared in estrogen-stimulated uteri from control versus neonatally DES-treated hamsters. According to Northern blot analysis of total uterine RNA, levels of the 3.2-kb c-jun and 2.4-kb c-myc transcripts were not altered by neonatal DES treatment. However, the 1.0 kb bax and 2.7 kb bcl-x transcript levels were significantly increased in the neonatally DES-exposed uteri. According to immunohistochemical analysis of paraformaldehyde-fixed and paraffin-embedded tissue sections, levels of c-Jun, c-Fos, c-Myc, Bax, and Bcl-x proteins were enhanced dramatically in both the luminal and glandular epithelial cells of neonatally DES-exposed uteri. In contrast, the immunostaining signal for Bcl-2 protein was decreased consistently in the epithelial cells of neonatally DES-exposed uteri. In conclusion, neonatal DES treatment induced persistent and epithelial cell-specific imbalances in the estrogen-regulated uterine expression of c-jun, c-fos, c-myc, bax, bcl-2, and bcl-x proto-oncogenes. These imbalances likely play a role in the molecular mechanism by which neonatal DES treatment induces altered estrogen responsiveness including hyperplasia, apoptosis, and ultimately neoplasia in the epithelial compartment of the hamster uterus.

Animals↗

Endometrial hyperplasia and apoptosis following neonatal diethylstilbestrol exposure and subsequent estrogen stimulation in both host and transplanted hamster uteri.

Prenatal exposure to the synthetic estrogen diethylstilbestrol (DES) causes morphogenetic alterations and neoplasia in the human reproductive tract. In the hamster, neonatal DES exposure alters early uterine morphogenesis and induces endometrial adenocarcinomas in adults. We now demonstrate that the preneoplastic stages of this phenomenon in the hamster reflect an abnormal uterotropic response to estrogen that is characterized by hyperplastic lesions in the endometrial epithelium and includes an immune and/or inflammatory component. Interestingly, biochemical and in situ analysis revealed that the hyperplastic epithelium is also an active site of cell death by apoptosis. To further probe the mechanism of this phenomenon, uteri from 7-day-old control or DES-exposed donors were transplanted into the cheek pouches of control or neonatally DES-exposed adult hosts, and both host groups were treated to provide high circulating levels of estradiol. Among the four ectopic scenarios, histopathological lesions (epithelial hyperplasia, dysplasia, and apoptosis), segregated almost exclusively to the two that consisted of neonatally DES-exposed uteri. The virtual absence of lesions in control uteri transplanted to DES hosts eliminated host systemic factors as causative agents. Therefore, we conclude that DES or its metabolites alter the cellular physiology and/or composition of the developing uterus (initiating event) in such a way that it thereafter responds abnormally to estrogenic stimulation (promoting event). These observations serve to further define a unique experimental system for probing: (a) various aspects of the clinical "DES Syndrome"; (b) how estrogen regulates normal uterine growth and morphogenesis; and (c) how this process can degenerate to the unregulated neoplastic state.

Animals↗

[The effect of prenatal diethylstilbestrol treatment on 1,2-dimethylhydrazine-induced carcinogenesis in C3HA female mice].

C3HA female mice received 0.1-0.3 mg/g body weight diethylstilbestrol (DES) on day 17 of gestation. Their descendants received a total of 20 injections of 1.2-dimethylhydrazine (DMH), subcutaneously, weekly, starting from month 2. Prenatal DES significantly inhibited the development of DMH-induced clitoral gland tumors, particularly, hemorrhagic ovarian cysts which were the frequent cause of death due to their rupture into the abdominal cavity. A significant decrease in cyst incidence resulted in higher survival in mice receiving combined therapy. The results were attributed to DES-induced hyperestrogenization which was confirmed by vaginal smears examination.

1,2-Dimethylhydrazine↗

1,2-Dimethylhydrazine carcinogenesis in C3HA and CBA female mice prenatally treated with diethylstilbestrol.

C3HA and CBA female mice received a single intraperitoneal (i.p.) injection of 0.1 or 0.3 mg/kg body weight (b.w.) of diethylstilbestrol (DES) at day 17 of pregnancy. The descendants, starting from the age of 2-3 months, were receiving weekly subcutaneous (s.c.) injections of 1,2-dimethylhydrazine (DMH) (8 mg/kg b.w.), total 20 injections. The survival of C3HA mice treated with DMH together with prenatal DES was considerably better than in mice treated with DMH alone, this being due to the strong inhibiting effect of DES on the induction by DMH of the hemorrhagic ovarian lesions (78.4% in DMH alone vs. 53.3 and 43.7% in groups with DES plus DMH), which frequently were the cause of animal death. Prenatal DES also inhibited the induction by DMH of clitoral gland tumors: 51.4% in the group with DMH alone vs. 26.6 and 28.1% in two groups of DES plus DMH, respectively. DES treatment, at the above doses, did not influence significantly the DMH carcinogenesis in CBA mice. Prenatal DES given to CBA mice at the dose of 1 mg/kg b.w. significantly increased the incidence of DMH-induced uterine sarcomas (42.8% vs. 73.3% in the group with DMH alone and the group receiving DMH together with prenatal DES, respectively) and accelerated their growth. The effects of prenatal DES on DMH-induced carcinogenesis correlated with the degree of hyperestrogenization produced in both strains of mice by DES.

1,2-Dimethylhydrazine↗